Akero Therapeutics Inc (NASDAQ: AKRO)’s stock price has dropped by -6.56 in relation to previous closing price of 20.26. Nevertheless, the company has seen a loss of -7.70% in its stock price over the last five trading days. Zacks Investment Research reported 2024-03-05 that Akero (AKRO) reports positive results from its mid-stage study of efruxifermin in pre-cirrhotic metabolic dysfunction-associated steatohepatitis patients at week 96. The stock gains 12%.
Is It Worth Investing in Akero Therapeutics Inc (NASDAQ: AKRO) Right Now?
Moreover, the 36-month beta value for AKRO is -0.31. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for AKRO is 57.79M and currently, short sellers hold a 14.16% of that float. On April 26, 2024, AKRO’s average trading volume was 1.38M shares.
AKRO’s Market Performance
The stock of Akero Therapeutics Inc (AKRO) has seen a -7.70% decrease in the past week, with a -22.39% drop in the past month, and a -14.19% fall in the past quarter. The volatility ratio for the week is 5.60%, and the volatility levels for the past 30 days are at 5.07% for AKRO. The simple moving average for the last 20 days is -15.44% for AKRO’s stock, with a simple moving average of -34.90% for the last 200 days.
Analysts’ Opinion of AKRO
Many brokerage firms have already submitted their reports for AKRO stocks, with BofA Securities repeating the rating for AKRO by listing it as a “Neutral.” The predicted price for AKRO in the upcoming period, according to BofA Securities is $30 based on the research report published on April 22, 2024 of the current year 2024.
Cantor Fitzgerald, on the other hand, stated in their research note that they expect to see AKRO reach a price target of $69. The rating they have provided for AKRO stocks is “Overweight” according to the report published on September 19th, 2023.
UBS gave a rating of “Buy” to AKRO, setting the target price at $83 in the report published on August 28th of the previous year.
AKRO Trading at -23.21% from the 50-Day Moving Average
After a stumble in the market that brought AKRO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -67.57% of loss for the given period.
Volatility was left at 5.07%, however, over the last 30 days, the volatility rate increased by 5.60%, as shares sank -22.58% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -8.06% lower at present.
During the last 5 trading sessions, AKRO fell by -7.70%, which changed the moving average for the period of 200-days by -57.79% in comparison to the 20-day moving average, which settled at $22.11. In addition, Akero Therapeutics Inc saw -18.93% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AKRO starting from Young Jonathan, who sale 5,000 shares at the price of $24.38 back on Apr 01 ’24. After this action, Young Jonathan now owns 263,306 shares of Akero Therapeutics Inc, valued at $121,913 using the latest closing price.
Cheng Andrew, the President and CEO of Akero Therapeutics Inc, sale 1,969 shares at $28.33 during a trade that took place back on Mar 13 ’24, which means that Cheng Andrew is holding 589,447 shares at $55,782 based on the most recent closing price.
Stock Fundamentals for AKRO
Current profitability levels for the company are sitting at:
- -608.7 for the present operating margin
- 0.49 for the gross margin
The net margin for Akero Therapeutics Inc stands at -525.68. The total capital return value is set at -0.31. Equity return is now at value -35.22, with -32.40 for asset returns.
Based on Akero Therapeutics Inc (AKRO), the company’s capital structure generated 0.05 points at debt to capital in total, while cash flow to debt ratio is standing at -5.76. The debt to equity ratio resting at 0.05. The interest coverage ratio of the stock is -55.78.
Currently, EBITDA for the company is -172.84 million with net debt to EBITDA at 1.33. When we switch over and look at the enterprise to sales, we see a ratio of 3862.72. The liquidity ratio also appears to be rather interesting for investors as it stands at 29.27.
Conclusion
To wrap up, the performance of Akero Therapeutics Inc (AKRO) has been bad in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
